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This article refers to ‘Potassium and the use of
renin–angiotensin–aldosterone system inhibitors in
heart failure with reduced ejection fraction: data from
BIOSTAT-CHF’ by J.C. Beusekamp et al., published in this
issue on pages 923–930.
For clinicians caring for patients with heart failure (HF),
acute or chronic kidney disease (CKD), and/or diabetes mel-
litus, dyskalaemia and optimization of diuretics and renin–
angiotensin–aldosterone system inhibitors (RAASi) are everyday
concerns. Although we understand cellular and renal potassium
regulation, surprisingly little is known about the causal relationships
between these syndromes, drug effects, and outcomes.
In this issue of the Journal, Beusekamp et al.1 studied potassium,
use of RAASi drugs, and outcomes in patients with HF and reduced
ejection fraction (HFrEF) from the well characterized longitudinal
BIOSTAT-CHF cohort. At baseline, hypokalaemia (K< 3.5 mEq/L)
was present in 6.9% and hyperkalaemia (K> 5.0 mEq/L) in 8.0%.
In unadjusted and adjusted Cox models, neither hypo- or hyper-
kalaemia, nor increases or decreases in potassium at 9 months,
were significantly associated with the composite outcome of
all-cause death or HF hospitalization up to 2 years. However,
in univariable and several multivariable logistic regression mod-
els, higher baseline potassium was associated with lower odds of
angiotensin-converting enzyme inhibitor (ACEi)/angiotensin recep-
tor blocker (ARB) uptitration. So is hyperkalaemia a risk marker or
a risk factor for poor outcomes in HF?
Does dyskalemia cause poor outcomes? Several studies indicate
that the relationship between potassium and outcomes exhibits a
U-shaped relationship in HF and/or CKD.2,3 However, the extent
of multivariable adjustment in these studies has been variable. In
the present analysis, hypo- or hyperkalaemia were not significantly
associated with outcomes. However, the sample size of 1666 was
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. modest and a closer examination reveals nominal hazard ratios
substantially above 1.0 for baseline hypo- but not hyperkalaemia.
Similarly, in a study of 13 015 patients in the Swedish HF Registry,
in univariable analysis, the relationship between potassium and
long-term outcomes was U-shaped, but in multivariable anal-
yses, hypo- but not hyperkalaemia was associated with worse
outcomes.4 Taken together, these data suggest that hyperkalaemia
is not a risk factor but a risk marker, but a risk marker for what?
Does hyperkalaemia attenuate the benefit of RAASi drugs?
In RALES5 and EMPHASIS-HF6 the benefit of mineralocorticoid
receptor antagonists was independent of potassium levels and
persisted even with severe hyperkalaemia. In BIOSTAT-CHF,
there was no interaction between baseline potassium, potassium
increases, or 9-month potassium levels and the benefit of upti-
trating RAASi. In an analysis of patients with estimated glomerular
filtration rate (eGFR) <30 mL/min/1.73 m2 in the Swedish HF
Registry, ACEi/ARB use was associated with the same benefit as
in patients with eGFR ≥30 mL/min/1.73 m2, and as demonstrated
in randomized trials of ACEi/ARB in HFrEF.7
So what is the problem with hyperkalaemia? We believe
BIOSTAT-CHF and other studies show that it is primarily not
a risk factor but a risk marker that leads to suboptimal use of
RAASi, especially mineralocorticoid receptor antagonists, which
in turn is causative in poor outcomes (Figure 1). Numerous stud-
ies have demonstrated suboptimal use and/or dosing of RAASi
in the real world, that this underuse is associated with worse
outcomes,8–11 and that quality improvement efforts improve use
of evidence-based HF drugs and ultimately outcomes.12 In the
present analysis, the salient finding was that hyperkalaemia at base-
line was associated with failure to uptitrate RAASi, consistently in
univariable analysis and in several multivariable models.
What can be done? Taken together, these findings suggest that
the main goal for patients with HFrEF and concomitant CKD
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Figure 1 Hyperkalaemia is a risk marker for poor out-
comes by leading to dose reduction or discontinuation of
renin–angiotensin–aldosterone system inhibitors (RAASi).
and/or hyperkalaemia should be to optimize RAASi use. This can
potentially be achieved by diligent monitoring of renal function
and electrolytes and persistence in attempting to introduce and
uptitrate these agents. Indeed, while eGFR <30 mL/min/1.73 m2 or
potassium >5.0–5.2 mEq/L were exclusion criteria for most RAASi
drug trials, the European Society of Cardiology HF guidelines
recommend that these drugs not be dose-reduced or discontinued
until potassium goes above 5.5 mEq/L.13 Another possibility is using
novel potassium binders to enable RAASi use. Both patiromer
and sodium zirconium cyclosilicate were shown to be effective
in lowering potassium and maintaining normokalaemia in patients
with HF and hyperkalaemia.14,15 Whether such a strategy can
enable use of RAASi agents and translate into improved outcomes
in patients with HFrEF and CKD and/or hyperkalaemia remains to
be shown.
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